LTZ Therapeutics Secures $38 Million in Funding to Advance First-in-Class Myeloid Cell Engager Immunotherapy Pipeline

May 2026JuneDay,LTZ Therapeutics（LTZ Therapeutics, hereinafter referred to as“LTZ”Or“Company”), announcedCompleted3800Million USDFinancing。This round of financing was led byGL Ventures (GL Ventures) led the investment. A large international sovereign wealth fund followed with a significant investment. Multiple existing shareholdersAdditional Investment, Including a Global Pharmaceutical Giant, Boyu Venture Capital (Boyu Growth Ventures), Five Source Capital (5Y Capital), BlueRun Ventures (Lanchi Ventures), Duxiu Capital (Unicorn Capital Partners) andShunwei Capital (Shunwei Capital）。From2022Since its establishment in the year,LTZHas cumulatively raised approximately1.3Billion US dollars。

Based onThe world's first proprietary technology platform——U-MCE™（Universal Myeloid Cell Engager），LTZWill use this round of fundraising to accelerate the advancement of "Myeloid Cell Engager" (MCE) Immunotherapy pipeline, especially the core products targeting cancer and autoimmune diseasesLTZ-301, supporting its ongoing recruitment of subjects at multiple renowned clinical centers across the United States.IPhase clinical research; meanwhile, promote the second candidate drugLTZ-232New Drug Clinical Trial Application (IND) andIPhase Clinical Initiation.

LTZFounder and CEO, Dr. Jinze Li (Dr. Robert Li）Expressed: "Sincere gratitude to both new and existing investors for their high level of trust. The successful completion of this round of financing will empowerLTZA strategic leap from technical platform validation to the realization of clinical value, helping usU-MCEThe scientific breakthroughs of the technology platform are truly transformed into clinical benefits for a wide range of patients. WithLTZ-301Successfully Launched in the United StatesIPhase Clinical,Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (r/r NHL), andLTZ-232To Be SubmittedINDWe are pushing forward the pipeline development at full speed. With the strong support of our investors, we look forward to accelerating the clinical translation of novel immunotherapies, fully leveraging the tremendous potential of myeloid cell biology, and effectively addressing significant unmet clinical needs in the fields of oncology and autoimmune diseases."

GL Ventures (GL Ventures）Project LeaderStated: "Myeloid Cell ConnectorIn tumors andAutoimmuneThe therapeutic potential in diseases is drawing global attention from the pharmaceutical industry.LTZRelying on the unique U-MCETechnologyPlatform, combining macrophage activation with tumor microenvironment remodeling, opens up an innovative mechanism pathway with differentiated advantages. InThe Past 10Within months,CompanyWith multinational pharmaceutical companies such as Eli Lilly,GSKThe intensive conclusion of significant transactions fully demonstrates the international industry market'sLTZDual Recognition of R&D Strength and Commercial Value. The rapid advancement of the pipeline alsoDemonstrate the company's discovery, translation, and clinical developmentFirst-in-ClassMedicineSystem capabilities and efficient execution. We will continue to supportLTZ", looking forward to working with founder Dr. Jinze Li and the team to advance their innovative therapies, bringing breakthrough treatment options to more patients."

With the completion of this round of financing,LTZOfficial AppointmentErin LavelleMs.As an Independent Director of the Company。LavelleThe woman recently served as the (ProfoundBio, hereinafter referred to as "LTZ Therapeutics") Chief Financial Officer (CFO`) and Chief Operating Officer (`COO). During the term of office,She successfully led the acquisition of Propharm by Denmark.GenmabIn18The milestone transaction of the US$ billion acquisition, and the oversubscription prior to the acquisition1.12Billion US dollarsBRound of Financing, and take the lead in advancing the preparations for Putro's market launch."Warm WelcomeErinJoin the Board of Directors,"Dr. Jinze Li added," ErinDeeply Cultivating the Biomedical Industry for Over25Year, with rich practical experience in operating and managing large multinational pharmaceutical enterprises and biotech startups, private enterprises and listed companies. InLTZThe key milestones in rapidly advancing clinical pipelines and global layout will become our valuable strategic assets, with her deep accumulation and international perspective boosting the company's global operational capabilities."

About Scientific Principles

LTZThe R&D strategy is deeply integrated“Reverse Translational Science”（Reverse Translational Science) and for“Tumor Microenvironment”A profound understanding of biology (especially myeloid cell biology). Macrophages are one of the most abundant immune cell populations in the tumor microenvironment of various hematologic malignancies and solid tumors. Therefore, effectively mobilizing and activating macrophages to kill tumor cells holds significant therapeutic potential for a broad patient population.LTZ Is independently developing a completely newU-MCEA technology platform aimed at enhancing the phagocytic function of macrophages and monocytes under different polarization states, targeting a variety of indications in both tumor and non-tumor fields, and building a broad-spectrum immune therapeutic barrier.

AboutLTZ-301

LTZ-301It is a novel "myeloid cell engager" bispecific antibody, throughGuide Macrophages and Monocytes to Target and ClearCD79bPositiveBCells, enhancing the phagocytosis and efficient clearance of tumor cells.CD79bIt is a specific tumor antigen receptor, inBHighly expressed in malignant tumors, including existingCD19OrCD20Cases of relapse and refractory after targeted therapy. Currently,LTZ-301Currently underway in the United StatesIPhase clinical research, widely recruiting from multiple well-known clinical centersRelapsed or Refractory Non-Hodgkin Lymphoma (r/r NHL）Patient.Preclinical studies have shown that,LTZ-301It demonstrated robust pharmacological activity in both in vitro and in vivo models, with a favorable safety profile.

About LTZ Therapeutics (LTZ Therapeutics）

LTZLTZ Therapeutics is a clinical-stage biotechnology company focused on novel immunotherapy, with core operations based in Redwood City, California, and Shenzhen, China. Targeting a broad spectrum of indications in the fields of oncology and autoimmune diseases, the company builds upon its self-developed technologies.U-MCE™（Universal Myeloid Cell Engager）A technology platform dedicated to developing "myeloid cell engagers" as innovative immunotherapeutic drugs, aiming to enhance clinical benefits for a wide range of patients.

Copyright © 2026 PHARMCUBE. All Rights Reserved. Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.